Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise

Simply Wall St.01-23

Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605414022?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-23 02:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605414022","market":"sg","top_or_hot":-1,"title":"Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise","media":"Simply Wall St.","content":"<div>\n<p>Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-valuation-after-2026-gene-therapy-u\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-23 02:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-valuation-after-2026-gene-therapy-u><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-valuation-after-2026-gene-therapy-u\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-valuation-after-2026-gene-therapy-u","article_id":"2605414022","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-valuation-after-2026-gene-therapy-u","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605414022","pubTimestamp":1769106859,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that extends its cash runway.\nSee our latest analysis for Tenaya Therapeutics.\nAt a recent share price of US$0.72, Tenaya’s 1 day share price return of 1.95% follows a 90 day share price return decline of 57.39% and a 1 year total shareholder return decline of 44.07%. This suggests that near term...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","TNYA":"Tenaya Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Tenaya Therapeutics(TNYA)2026年基因疗法更新和6000万美元融资后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":1.5},"content_text":"Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that extends its cash runway. See our latest analysis for Tenaya Therapeutics. At a recent share price of US$0.72, Tenaya’s 1 day share price return of 1.95% follows a 90 day share price return decline of 57.39% and a 1 year total shareholder return decline of 44.07%. This suggests that near term momentum is tentative after a difficult stretch for longer term holders. If you are looking beyond a single biotech name, this could be a good moment to scan other healthcare opportunities using our healthcare stocks as a starting point. With the stock around US$0.72 after steep 1 year and 3 year total return declines, plus a recent US$60 million raise and ambitious 2026 data plans, is Tenaya a mispriced heart disease gene therapy player, or is the market already factoring in its potential? AdvertisementPrice-to-Book of 1.9x: Is it justified? At a last close of US$0.72, Tenaya trades on a P/B of 1.9x, which screens as lower than both its peer group and the wider US biotechs industry. P/B compares the market value of the company to its net assets on the balance sheet. It is often used for early stage or loss making biotechs where earnings and revenue are still limited. Here, Tenaya’s 1.9x P/B sits below the peer average of 2.7x and the US biotechs industry average of 2.6x. This suggests the market is pricing the company’s assets at a discount to similar names despite its focus on clinical stage heart disease programs. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 1.9x (UNDERVALUED) However, you still need to weigh risks such as clinical trial setbacks across TN-201, TN-401 or TN-301, as well as ongoing net losses of US$94.258 million. Find out about the key risks to this Tenaya Therapeutics narrative.  Build Your Own Tenaya Therapeutics Narrative If you see the numbers differently or prefer to test your own assumptions, you can build a customised view of Tenaya in minutes using Do it your way. A great starting point for your Tenaya Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? If Tenaya has your attention, do not stop there. Cast a wider net with other ideas that might fit your style and risk tolerance.  Spot potential high risk, high reward names early by scanning these 3535 penny stocks with strong financials that already clear basic financial strength checks. Ride the AI wave thoughtfully by checking out these 24 AI penny stocks that focus on companies applying artificial intelligence across different sectors. Focus on valuation discipline by reviewing these 882 undervalued stocks based on cash flows that screen for stocks priced below estimated cash flow potential.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tenaya Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605414022","isCrawlerRequest":true}